For instance, Michael D Farwell et al. conducted a phase I trial of PET/CT scan with 89Zr-labeled IAB22M2C minibody targeting CD8+ cells, which visualized the biodistribution of tumor-infiltrating CD8+ T cells and predicted early response to immunotherapy (Farwell et al., 2021). The gene discussed is CD8A; the disease is neoplasm.